Robert T.S. Latta (Rob)

Partner

San Diego + 1.858.314.1140

Collegati

Condividi

Rob Latta is an intellectual property transactions lawyer focusing on life sciences, artificial intelligence, and advanced technology. He advises clients on a range of life science, agrifood, and high‑technology transactions, including licensing, strategic alliances, joint ventures, confidentiality, manufacturing, supply, and distribution agreements. Rob's technical background, coupled with extensive experience working within both life sciences and technology‑driven businesses, allows him to bridge the gap between life sciences and computer sciences industries, particularly in matters involving computational biology, bioinformatics, and data‑enabled technologies.

Rob has extensive experience negotiating complex cross‑border collaboration agreements, particularly between the United States and South America, Europe, and Asia, including technology‑driven and data‑intensive collaborations and the establishment of multiparty international drug registries. He also assists clients with evaluating intellectual property and data rights in high‑stakes due diligence and negotiates to secure optimal IP positions in connection with the acquisition or divestment of assets in the United States and abroad.

Rob has worked with leading companies in the life sciences, environmental, industrial, and technology sectors, such as Astellas, Athersys, Biomarin, Celgene, Cibus, Granite Construction, Milliken, NorthStar Group, Organon, Procter & Gamble, and Sanofi.

Rob's technical experience includes small molecule, biologics, gene editing and therapy, medical devices, data management, artificial intelligence, software, and electrical engineering.

Prior to joining Jones Day, Rob was an associate in the San Diego offices of two international law firms, where he predominantly worked in patent prosecution and assisted in patent litigation and technology‑based transactions. At the start of his career, he practiced intellectual property law in the Columbus, Ohio office of a national law firm.

Esperienze

  • EagleTree acquires The Opus GroupJones Day advised EagleTree Capital in the acquisition and financing of The Opus Group, a purpose-built network of agency brands delivering experiential, event and brand marketing for more than 70 global companies.
  • Verily spins out from Alphabet and raises $300 millionJones Day represented Verily Health in its spin-out from Alphabet, Inc., corporate restructuring and $300 million new money financing.
  • Radial Equity Partners acquires Thomas Precision MachiningJones Day advised Radial Equity Partners in the investment in and financing of Thomas Precision Machining, a leading provider of replacement parts, service and equipment for industrial processing applications, primarily serving the protein and food processing industries.
  • Wabtec acquires Dellner CouplersJones Day advised Wabtec Corporation in the $960 million acquisition of Dellner Couplers, a global leader in highly engineered safety-critical train connection systems and services for passenger rail rolling stock.
  • Center Rock Capital Partners acquires Stoneridge Control DevicesJones Day advised Center Rock Capital Partners in the acquisition of Stoneridge Control Devices, Inc., a division of Stoneridge, Inc. (NYSE: SRI).
  • Guess? co-founders Maurice and Paul Marciano and CEO Carlos Alberini Partner with Authentic Brands Group to take Guess? privateJones Day advised the co-founders and Chief Executive Officer of Guess?, Inc. (NYSE: GES) in their strategic partnership with Authentic Brands Group LLC pursuant to which Authentic acquired 51% of substantially all Guess? intellectual property and all of the outstanding common stock of Guess? not owned by the rolling stockholders at $16.75 per share in an all-cash transaction that values Guess? at approximately $1.4 billion, including debt.
  • Invitation Homes acquires ResiBuiltJones Day advised Invitation Homes Inc. in the acquisition of ResiBuilt Homes, LLC, a leading build-to-rent (“BTR”) developer in high-growth markets across the Southeast.
  • West Pharmaceutical Services sells manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System to AbbVieJones Day is advising West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, in the sale of all manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for $112.5 million at close, subject to working capital and other adjustments.
  • Radial Equity portfolio company acquires CortinaJones Day advised Radial Equity Partners in the acquisition and financing by portfolio company Plasticade of Cortina, a leading manufacturer of traffic and work zone safety products, bringing together two of the strongest and most well-known brands in the traffic safety products industry.
  • Riverside Company sells Trustwell to TPGJones Day advised The Riverside in the sale of Trustwell, a leading provider of SaaS-based compliance, safety and supply chain solutions for the food industry, to TPG’s The Rise Fund, the multi-sector strategy of TPG’s global impact investing platform.
  • BioMarin acquires Amicus Therapeutics for $4.8 billionJones Day is advising BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) in its $4.8 billion acquisition of Amicus Therapeutics (Nasdaq: FOLD).
  • AAR acquires Aircraft Reconfig TechnologiesJones Day is representing AAR Corp. in its acquisition of Aircraft Reconfig Technologies, a leading aircraft interiors engineering company, from ZIM Aircraft Cabin Solutions for $35 million in an all-cash transaction, subject to customary adjustments.
  • Private credit fund purchases subordinated notes and warrants in amount of $100 millionJones Day advised a private credit fund in connection with the purchase of subordinated notes and warrants in the aggregate principal amount of $100 million, the proceeds of which were used to finance the acquisition of a cloud-based SaaS platform in the digital advertising space.
  • Stance sold to Marquee BrandsJones Day represented Stance, Inc., a lifestyle and performance sock and apparel company, in connection with a sale of substantially all of its assets to Marquee Brands.
  • TreeHouse Foods goes private in $2.9 Billion sale to InvestindustrialJones Day is representing TreeHouse Foods, Inc. (NYSE: THS) in a $2.9 billion take-private transaction whereby an affiliate of Investindustrial, a leading European group of independently managed investment, holding, and advisory companies, will acquire TreeHouse Foods in an all-cash transaction.
  • EagleTree Capital sells Northstar Travel Group to JTB Corp.Jones Day advised EagleTree Capital in the sale of Northstar Travel Group, a leading B2B travel industry events, media, and information services company, to JTB Corp., one of Japan’s leading travel solutions providers.
  • AAR acquires ADI American DistributorsJones Day advised AAR Corp. in the $146 million acquisition of ADI American Distributors Holding Co., LLC, a leading distributor of components and assemblies.
  • Block Communications sells television stations to Gray MediaJones Day is advising Block Communications, Inc. in the sale of its television stations to Gray Media, Inc.
  • M&T leads syndicate of lenders on $150 million senior secured credit facility for Transcat, Inc.Jones Day represented Manufacturers and Traders Trust Company (M&T), as administrative agent, in connection with a $150 million syndicated senior secured credit facility provided to Transcat, Inc., a global leader in test and measurement equipment and calibration services for highly technical industries.
  • Wabtec acquires Evident’s inspection technologies divisionJones Day advised Wabtec Corporation (NYSE: WAB) in connection with its $1.78 billion acquisition of Evident’s inspection technologies division, a global leader in non-destructive testing, remote visual inspection and analytical instruments solutions for mission critical assets.
    •

    November 2024 Reprint

    Patent Licensing (The Licensing Journal)

    May 2024 Commentary

    NIH Seeks Comments on Patient Access Plan Requirements in Patent License Agreements

    September 2023 Newsletters

    Vital Signs Digital Health Law Update | Summer 2023

    August 2023 Commentary

    Generative AI End-User License Agreements: What Users Need to Know

    Prima di procedere all'invio, si prega di notare:

    il contenuto del presente sito web è a scopo esclusivamente informativo e non può essere considerato un parere legale o altro tipo di consulenza professionale. L'invio o la ricezione della presente email non è atta ad instaurare alcun rapporto cliente/avvocato. Le informazioni inviate tramite questa funzione al nostro Studio non saranno coperte da vincolo di riservatezza o confidenzialità fintanto che non ci sia stato conferito e non sia stato da noi accettato un incarico professionale. Inviando il messaggio confermate di aver preso visione e accettato il contenuto di questa informativa.